PPM1D and myelodysplastic syndrome: Based on the modified classifier from Lindsley et al, CR rates of “TP53/PPM1D,” “MDS-like,” and “de novo/pan-AML” were 36% (n = 10/28), 37% (n = 7/19), 83% (n = 25/30) (P = 0.0003).